MSD Initiates Phase III Trial for PCSK9 Inhibitor MK-0616 in LDL Cholesterol Reduction
Merck, Sharp & Dohme (MSD; NYSE: MRK) has commenced Phase III development for its experimental...
MSD
AstraZeneca and MSD’s Lynparza Gets Green Light for Prostate Cancer Treatment in Japan
Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted AstraZeneca (AZ; NASDAQ: AZN) and...
MSD’s Welireg Meets Primary Endpoint in Phase III RCC Study but Misses OS Milestone
Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed that the ongoing Phase III study...
MSD’s Q2 2023 Earnings: Keytruda and Gardasil Drive Growth Amid COVID-19 Sales Decline
US-based major Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial results...
MSD’s V116 Vaccine Shows Superior Immune Response in Phase III Trials
Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed positive topline results from two Phase...
Johnson & Johnson Files Lawsuit Against US Government’s Drug Pricing Negotiation Authority
United States-based Johnson & Johnson (J&J, NYSE: JNJ) has filed a lawsuit this week, challenging...
Sichuan Kelun-Biotech Biopharmaceutical Prices IPO at HKD 60.6 to 72.8 per Share
Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co.,...
Sichuan Kelun’s SKB264 Earns Breakthrough Therapy Designation for Breast Cancer Treatment
The Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Kelun Pharmaceutical Co.,...
Wuhan Institute’s Hexavalent Rotavirus Vaccine on Track for Priority Review by CDE
The Center for Drug Evaluation (CDE) website has indicated that Wuhan Institute of Biological Products...
Q1 2023 financial report: AstraZeneca leads innovation in China, Sanofi’s sales in China decline
Several multinational companies (MNCs) have released their Q1 2023 financials, showing a varied performance over...
GSK’s Cervarix Receives Approval for Two-Dose Schedule in China for Ages 9 to 14
The UK-based pharmaceutical giant GSK plc (NYSE: GSK) has announced the official market launch of...
Evopoint Biosciences Partners with Merck for Phase Ib/II Study Combining XNW5004 and Keytruda
China-based Evopoint Biosciences has announced a collaboration agreement with US major Merck Sharp & Dohme...
Legend Biotech Corporation Appoints Industry Veterans to Strategic Advisory Board
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced the formation of a strategic advisory board...
BJ Bioscience Partners with MSD for Phase I Clinical Trial of BJ-001 and Keytruda
Shanghai-based biotech BJ Bioscience Inc. has announced a clinical trial collaboration and supply agreement with...
Merck & Peking University Launch Public Health Training Projects for Young and Middle-Aged Talent
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and the Peking University School of Public...
Jacobio Pharma Partners with Merck to Evaluate CD73 mAb and Keytruda Combination
China-based Jacobio Pharma (HKG: 1167) has announced a clinical partnership with Merck, Sharp & Dohme...
Sumitomo Pharma Secures Rights to Vibegron for Asian Markets
Japan-based Sumitomo Pharma Co., Ltd has signed a sub-license deal with compatriot firm Kyorin Pharmaceutical...
Zhifei Renews Vaccine Supply Agreement with Merck Sharp & Dohme
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the renewal of a supply,...
MSD China to Take Legal Action Against Market Infringement of Molnupiravir
Merck Sharp & Dohme (MSD, NYSE: MRK)’s China unit has issued a WeChat notification vowing...
Kelun-Biotech’s SKB264 Approved for Phase II Study in EGFR-Mutant NSCLC
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the National Medical Products...